Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

How Escherichia coli infects the urinary tract

Article Abstract:

Urinary tract infections are produced by bacteria growing in the bladder and potentially infecting the kidney. Treatment with appropriate antibiotics usually cures the urinary tract infection. Some women are more susceptible to repeated urinary tract infections inspite of successful treatment. It has been found that receptors on the cells lining the urinary tract are affected by the carbohydrate composition of the cell membrane. This in turn can influence the affinity these receptors have for bacteria, particularly the most common urinary tact bacteria, Escherichia coli. A study found that women experiencing recurrent urinary tract infections have urinary tract cells which bind more easily to bacteria than those of healthy women. Evaluation of secretory cell status, vaccination with proteins to decrease the affinity between the receptors and the bacteria, or the use of solutions similar to the receptors which inhibit the bacterial adhesion may offer improved treatment over prophylactic antibiotic therapy.

Author: Schoolnik, Gary K.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1989
Analysis, Causes of, Urinary tract infections, Escherichia coli infections, Disease susceptibility, editorial

User Contributions:

1
Debora Stream
Report this comment as inappropriate
Feb 2, 2010 @ 6:06 am
I have re-ocurring uti's. My report said that it has greater then 100,000 colony forming unitets per mL. My dr. put me on Macrodurtine 100mg 4x a day. This is making me nausausious,diaher. I feel flushed also and with a low grade fever. This is really upsetting me because, I read where it said that it also can come from being unclean. I am a very clean person and I make sure that my body is clean. So what can cause this and how can I get rid of this?

Comment about this article or add new information about this topic:

CAPTCHA


Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors

Article Abstract:

The prevalence and transmissibility of influenza B viruses with reduced sensitivity to neuraminidase inhibitors was assessed at four community hospitals in Japan during the 2004-2005 influenza seasons. The results demonstrated that influenza B viruses with reduced sensitivity to neuraminidase inhibitors could emerge during routine therapy, appearing to be transmitted from person to person.

Author: Kawaoka, Yoshihiro, Sugaya, Norio, Koike, Kazuhiko, Mitamura, Keiko, Ito, Mutsumi, Kiso, Maki, Hatakeyama, Shuji, Yamazaki, Masahiko, Ichikawa, Masatak, Kimura, Kazuhiro, Shimizu, Hideaki, Kawakami, Chiharu
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
United States, Science & research, Health aspects, Research, Influenza viruses, Zanamivir, Oseltamivir phosphate, Clinical report, Viral drug resistance

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: Point of contact. 'One in three of us will end our lives with dementia'. Nursing an identity crisis
  • Abstracts: Exogenous reinfection in tuberculosis. Medical management of influenza infection
  • Abstracts: Therapeutic care increases independence. Managing inpatients who have personality disorders. Using psychosocial interventions within a high-security hospital
  • Abstracts: Arteriovenous malformations of the brain in adults. Major congenital malformations after first-trimester exposure to ACE inhibitors
  • Abstracts: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. part 2 Behavior problems and mental health referrals of international adoptees
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.